Elevated Stratifin promotes cisplatin-based chemotherapy failure and poor prognosis in non-small cell lung cancer

Drug resistance is a key factor in the treatment failure of clinical non-small cell lung cancer (NSCLC) patients after adjuvant chemotherapy. Here, our results provide the first evidence that eukaryotic translation initiation factor 2b subunit delta (EIF2B4)-Stratifin (SFN) fusion and increased SFN...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yu-Shui, Hou, Li-Kun, Yao, Shi-Hua, Liu, Ji-Bin, Yu, Xue-Chen, Shi, Yi, Yang, Xiao-Li, Wu, Wei, Wu, Chun-Yan, Jiang, Geng-Xi, Fu, Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426184/
https://www.ncbi.nlm.nih.gov/pubmed/34553022
http://dx.doi.org/10.1016/j.omto.2021.07.005
Descripción
Sumario:Drug resistance is a key factor in the treatment failure of clinical non-small cell lung cancer (NSCLC) patients after adjuvant chemotherapy. Here, our results provide the first evidence that eukaryotic translation initiation factor 2b subunit delta (EIF2B4)-Stratifin (SFN) fusion and increased SFN expression are associated with chemotherapy tolerance and activation of the phosphatidylinositol 3 kinase/v-akt murine thymoma viral oncogene (PI3K/Akt) signaling pathway in NSCLC patients, suggesting that SFN might have potential prognostic value as a tumor biomarker for the prognosis of patients with NSCLC.

Ejemplares similares